Optic Neuritis Treatment Guidelines

First-Line Treatment

High-dose intravenous methylprednisolone is the recommended first-line treatment for optic neuritis, administered at 1000 mg/day for 3 days, according to the World of Neurosurgery 1
Intravenous methylprednisolone at doses of 30 mg/kg up to 1000 mg/day has been shown to improve visual outcomes in most patients with optic neuritis, as recommended by the World of Neurosurgery 1, 2

For optic neuritis associated with systemic lupus erythematosus (SLE), pulse intravenous methylprednisolone in combination with intravenous cyclophosphamide is recommended, as stated by the Annals of the Rheumatic Diseases 3
In SLE-related optic neuritis, visual outcomes are generally poorer, with only 30% of patients maintaining visual acuity greater than 20/25, according to the Annals of the Rheumatic Diseases 4, 5
For patients with antiphospholipid antibodies not responding to immunosuppressive therapy, anticoagulation may be considered, as suggested by the Annals of the Rheumatic Diseases 3, 4

For refractory cases, additional immunosuppressive options include Rituximab (RTX), Azathioprine (AZA), and Plasma exchange (PLEX) in severe cases, as recommended by the World of Neurosurgery 1, 2

Treatment should be initiated promptly, as delay (>2 weeks) in therapy initiation is associated with poorer outcomes, according to the Annals of the Rheumatic Diseases 3
MRI of the brain and orbits with contrast is essential for diagnosis and to rule out other conditions, as stated by Praxis Medical Insights 6
Relapses are common (50-60%) during corticosteroid dose reduction, highlighting the need for maintenance immunosuppressive therapy in some cases, as reported by the Annals of the Rheumatic Diseases 4

Regular ophthalmological evaluations including visual acuity, visual fields, and funduscopy are necessary to monitor treatment response, as recommended by the Annals of the Rheumatic Diseases 3
Visual-evoked potentials may detect bilateral optic nerve damage before it becomes clinically apparent, according to the Annals of the Rheumatic Diseases 3, 4
Patients should be monitored for development of multiple sclerosis, as optic neuritis may be the first manifestation, as stated by the World of Neurosurgery 1

Combination therapy with pulse IV methylprednisolone and IV cyclophosphamide is recommended for Systemic Lupus Erythematosus-Associated Optic Neuritis, with visual outcomes generally poorer, and only 30% maintaining visual acuity greater than 20/25 7
IV methylprednisolone is the initial treatment for Neuromyelitis Optica (NMO)-Associated Optic Neuritis, with rituximab showing better efficacy than azathioprine in reducing relapse rates for refractory cases 8
Plasma exchange may be beneficial in severe cases of Neuromyelitis Optica (NMO)-Associated Optic Neuritis not responding to steroids 7, 8

Visual-evoked potentials may detect bilateral optic nerve damage before it becomes clinically apparent, particularly in patients with Systemic Lupus Erythematosus-Associated Optic Neuritis 7

Rituximab has shown efficacy in refractory cases of Neuromyelitis Optica (NMO)-Associated Optic Neuritis, particularly for patients not responding to initial treatments 8
Immunosuppressants such as azathioprine and mycophenolate may be used as steroid-sparing agents for maintenance therapy in refractory cases of optic neuritis 8, 9